A Study of Galcanezumab in Participants With Chronic Cluster Headache
Trial ID or NCT#
NCT02438826
Status
RECRUITING
Purpose
The main purpose of this study is to evaluate the efficacy of the study drug known as galcanezumab in participants with chronic cluster headache.
Official Title
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of : Galcanezumab (LY2951742) With a Long-Term Open-Label Extension in Patients With Chronic Cluster Headache
Eligibility Criteria
Ages Eligible for Study: 18 Years to 65 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No
Inclusion Criteria:
- - Participants with a history of chronic cluster headache occurring without a remission period, or with remissions lasting <1 month, for at least 1 year. - Participants are able to distinguish cluster headache attacks from other headaches.
Exclusion Criteria:
- - Current enrollment in or discontinuation within the last 30 days from, a clinical trial involving any investigational drug or device. - Current use or any prior exposure to any calcitonin-gene-related peptide (CGRP) antibody, any antibody to the CGRP receptor, or antibody to nerve growth factor (NGF). - Are taking indomethacin and/or are suspected of having another distinct trigeminal autonomic cephalalgia. - A history of migraine variants that could implicate or could be confused with ischemia. - Known hypersensitivity to multiple drugs, monoclonal antibodies or other therapeutic proteins. - A history or presence of other medical illness that indicates a medical problem that would preclude study participation. - Evidence of significant active or unstable psychiatric disease, in the opinion of the investigator. - Women who are pregnant or nursing.
Contact us to find out if this trial is right for you.
Contact
650-723-5184
View on ClinicalTrials.gov
